Lineage Cell Therapeutics Files Q1 2025 10-Q
Ticker: LCTX · Form: 10-Q · Filed: May 13, 2025 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotechnology, reporting
TL;DR
Lineage Cell Therapeutics filed its Q1 2025 10-Q. Financials and operations updated.
AI Summary
Lineage Cell Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations, including details on its common stock and equity incentive plans. Specific financial figures and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with an update on Lineage Cell Therapeutics' financial health and operational progress for the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — As a biotechnology company, Lineage Cell Therapeutics faces inherent risks related to research and development, regulatory approvals, and market adoption of its products.
Key Numbers
- Q1 --12-31 2025 — Fiscal Quarter End (Indicates the period covered by the report.)
- 2025-03-31 — Reporting Period End Date (Specifies the end date for the financial data presented.)
- 2024-01-01 2024-03-31 — First Quarter 2024 (Period for which comparative financial data might be presented.)
Key Players & Entities
- Lineage Cell Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250513 (date) — Filing date
- BIOTIME INC (company) — Former company name
- 2836 (dollar_amount) — Standard Industrial Classification code for Biological Products
FAQ
What is the reporting period for this 10-Q filing?
The reporting period is for the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 13, 2025.
What was the company's former name?
The company's former name was BIOTIME INC.
What is the Standard Industrial Classification code for Lineage Cell Therapeutics?
The SIC code is 2836, for Biological Products (No Diagnostic Substances).
Does the filing mention any specific equity incentive plans?
Yes, the filing references the 'TwoThousandTwentyOneEquityIncentivePlanMember'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Lineage Cell Therapeutics, Inc. (LCTX).